The study suggests standardized uptake values may be a useful marker to predict treatment response and prognosis in lung adenocarcinoma.
Maximum standardized uptake value (SUVmax) in lung adenocarcinomas correlates with programmed death ligand 1 (PD-L1) expression levels and may help predict immunotherapy response in patients with stage IV cancers, according to a new report published in Frontiers in Medicine.
Lung adenocarcinoma has a high mortality rate, the authors noted, particularly in developing countries where a significant number of patients do not receive their diagnosis until their cancers have reached stage IV. As therapy for lung adenocarcinoma has evolved, the study investigators said PD-L1 testing has become a routine procedure to help identify the most appropriate treatment. For some patients, PD-L1–targeting monoclonal antibodies can be used.
“The binding of programmed cell death protein 1 (PD-1) with PD-L1 induces T-lymphocyte depletion or death,” the authors noted. “The inhibition of this signaling pathway has been shown to increase T-cell activity, boost antitumor immunity, and prevent tumor cells from evading host immune responses, representing a viable technique for successful tumor immunotherapy.”
Previous investigations have attempted to figure out whether one way to ascertain PD-L1 levels might be to use SUVmax levels. SUVmax has already been identified as a prognostic indicator in both early and advanced non–small cell lung cancer (NSCLC), the authors noted. However, to date no study has looked specifically at the relationship between PD-L1 levels and SUVmax in NSCLC. Moreover, the authors said there has been little research examining PD-L1 expression in patients with NSCLC within the Vietnamese population.
The authors therefore decided to see whether they could use 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT values to predict PD-L1 expression among patients with stage IV lung adenocarcinoma who sought treatment from a single hospital in Vietnam.
The-constructed a cohort of 86 patients with stage IV disease who underwent both PET/CT imaging and PD-L1 expression testing between February 2019 and November 2020. The patients, two-thirds of whom were men, had an average age of 62.23 years and 36% had epidermal growth factor receptor (EGFR) mutations.
PD-L1 expression testing showed that 40.7% of cases were PD-L1 negative (meaning PD-L1 was detected in less than 1% of the tumor). In 32.6% of cases, PD-L1 was detected in 1% to 49% of the tumor, and in 26.7% of cases, PD-L1 was detected in more than 50% of the tumor.
The mean (SD) SUVmax value was 11.09 (3.94); however, it was notably higher in PD-L1–positive tumors (12.24 [4.01]) than in PD-L1–negative tumors (9.43 [3.22]). Moreover, they found that SUVmax was significantly different not only between PD-L1–positive and –negative cases, but also between tumors that were weakly expressing PD-L1 and those strongly expressing PD-L1.
“SUVmax is considerably higher in patients with positive PD-L1 expression than in those with negative PD-L1 expression,” the authors said. “This finding suggests that combining the evaluation of PD-L1 expression and SUVmax in the primary tumor may help predict stage IV adenocarcinoma lung cancer prognosis.”
The authors said the question of the relationship between PD-L1 expression and SUVmax remains controversial, and they said their study has limitations, including its cross-sectional nature and small study population. They said glutamine transporters and hexokinase II should be included in future studies and that further research is necessary to better understand whether and how 18F-FDG can be used to predict immunotherapy response.
Reference
Tien Cong B, Cam Phuong P, Thai PV, et al. Prognostic Significance of PD-L1 Expression and Standardized Uptake Values in the Primary Lesions of Stage IV Adenocarcinoma Lung Cancer. Front Med (Lausanne). Published online May 13, 2022. doi:10.3389/fmed.2022.895401
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More